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F umarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a rare condition that is 
characterized by inactivating mutations in the fumarate 
hydratase (FH) gene [1].  It is known to be a cause of 
hereditary leiomyomatosis and renal cancer syndrome 
(HLRCC),  an autosomal dominant disorder character-
ized by an inherited predisposition to early-onset uterine 
leiomyomas,  multiple cutaneous leiomyomas,  and renal 
cell carcinoma (RCC).  FH-deficient RCC commonly 
presents as a locally advanced or metastatic disease and 
portends a poor prognosis.  One report demonstrated 
that 71% of 32 patients with FH-deficient RCC presented 
with stage ≥ pT3a disease.  After a median follow-up of 
16 months (range,  1 to 118 months) in 26 patients,  19% 
showed no evidence of disease,  31% were alive with the 
disease,  and 50% had died of the disease [2].
Immunotherapy with nivolumab,  a programmed cell 
death protein 1 (PD-1) inhibitor and ipilimumab,  a 
cytotoxic T-lymphocyte antigen 4 (CTLA-4) inhibitor 
(Ipi/Nivo),  has recently become a standard and import-
ant treatment regimen for metastatic RCC.  Ipi/Nivo was 
approved as a first-line therapy for International Metastatic 
RCC Database Consortium (IMDC) intermediate- or 
poor-risk metastatic RCC by the U.S.  Food and Drug 
Administration (FDA) in 2018.  However,  to our knowl-
edge,  only one case of metastatic FH-deficient RCC 
treated with Ipi/Nivo has been previously reported [3].  
Herein we report a case of FH-deficient–like RCC (i.e.,  
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We report a 62-year-old male with metastatic fumarate hydratase-deficient renal cell carcinoma (FH-deficient 
RCC) without fumarate hydratase (FH) mutation (FH-deficient–like RCC).  The International Metastatic RCC 
Database Consortium risk score was intermediate,  and immunotherapy with nivolumab and ipilimumab (Ipi/
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a histologically compatible FH-deficient RCC without 
FH mutation).  Thirteen months after robot-assisted 
partial nephrectomy was performed,  lymph node and 
bone metastases occurred.  A renal hilar lymph node 
metastasis was the target lesion and Ipi/Nivo resulted in 
a complete response (CR).
Case Report
The patient is a 62-year-old Japanese male with a 
good performance status.  A renal mass was found inci-
dentally in a routine ultrasound examination.  His fam-
ily history included renal cancer in his maternal uncle,  
aunt,  and grandmother.  Contrast-enhanced computed 
tomography (CT) revealed a cystic lesion with enhanc-
ing mural nodules in the left kidney (Fig. 1).  The lesion 
was estimated to be 46 × 42 mm in size and the Bosniak 
classification was category IV.  No metastatic lesions 
were detected.  The tumor-node-metastasis clinical clas-
sification was T1bN0M0,  stage I.  He underwent robot- 
assisted partial nephrectomy.
The macroscopic appearance of the tumor was a well 
circumscribed lesion of 45 × 40 mm in size.  The surgical 
margin was negative.  Histologically,  the tumor showed 
papillary,  solid,  and tubular proliferation.  The tumor 
cells had eosinophilic cytoplasm and nuclei with prom-
inent nucleoli surrounded by halos (Fig. 2A).  
Immunohistochemically,  tumor cells were negative for 
FH,  cytokeratin 7,  cluster of differentiation 10 (CD10),  
and Wilms tumor 1 (WT-1) expression and positive for 
epithelial membrane antigen (EMA) and alpha-methy-
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Fig.  1　 CT with intravenous contrast medium showed a cystic 
lesion with enhancing mural nodules in the left kidney (yellow cir-
cle).  The lesion was deemed 46×42 mm and the Bosniak classifi-




Fig.  2　 A,  Hematoxylin and eosin (HE) staining shows papillary 
proliferation.  Inset.  The tumor cells had eosinophilic cytoplasm and 
nuclei with prominent nucleoli surrounded by halos; B,  
Immunohistochemical staining showed no expression of fumarate 
hydratase (FH) in neoplastic cells,  while capillary endothelial cells 
were positive for FH expression; C,  Tumor cells were negatively 
stained for programmed death ligand 1 (PD-L1).
lacyl-CoA racemase (AMACR) expression (Fig. 2B).  
Tumor cells were negative for programmed death ligand 1 
(PD-L1) expression (Fig. 2C).  There were no obvious 
tumor-infiltrating lymphocytes (TILs).  A histological 
diagnosis of FH-deficient RCC was made.
The patient’s postoperative course was uneventful.  
No recurrences were observed in the first 13 months after 
surgery.  Positron emission tomography and CT (PET-CT) 
at 13 months after surgery revealed left subclavicular,  
left renal hilar,  and para-aortic lymph node metastases.  
PET-CT also demonstrated bone metastasis at the left 
fifth rib.  The diameter of the hilar lymph node metasta-
sis was 16 mm,  which was the only target lesion eligible 
for response assessment according to the Response 
Evaluation Criteria in Solid Tumors (RECIST 1.1) crite-
ria (Fig. 3A).  The laboratory results were normal except 
for a diminished serum hemoglobin level of 13.3 g/dL 
(normal range,  13.7-16.8 g/dL),  so the IMDC-risk 
score was intermediate based on a hemoglobin level 
below the lower limit of the normal range.
The patient was offered systemic immunotherapy 
consisting of intravenous nivolumab 240 mg and ipilim-
umab 1 mg/kg.  These medications were administered 
every 3 weeks for 4 cycles,  followed by nivolumab 
240 mg alone every 2 weeks.  Just after the administra-
tion of Ipi/Nivo was initiated,  the patient experienced 
diarrhea (Grade 1 as per the Common Terminology 
Criteria for Adverse Events),  which improved without 
any specific treatment within a few days.  After 2 cycles 
of Ipi/Nivo,  re-staging CT showed a partial response of 
the hilar lymph node metastasis,  which was reduced to 
10 mm (Fig. 3B).  After 4 cycles of Ipi/Nivo,  he com-
plained of headache,  nausea,  and appetite loss for three 
days.  Laboratory results showed decreased levels of 
sodium (122 mmol/L; normal range,  138-145 mmol/L),  
low cortisol (0.5 μg/dL; normal range,  4.0-18.3 μg/dL),  
and low adrenocorticotropic hormone (ACTH) (1.8 pg/
mL; normal range,  7.2-63.3 pg/mL).  Pituitary mag-
netic resonance imaging revealed no evidence of abnor-
malities.  We suspected hypophysitis (Grade 3) as an 
immune-related adverse event (irAE).  Treatment was 
initiated with corticosteroids consisting of intravenous 
hydrocortisone 100 mg/day for 4 days followed by oral 
hydrocortisone 20 mg/day.  After the corticosteroid 
therapy,  the patient’s headache,  nausea,  and appetite loss 
improved,  and he has continued on oral hydrocortisone 
20 mg/day regularly since then.  Due to hypophysitis,  
one cycle of nivolumab was withheld and rescheduled 




Fig.  3　 A,  A 16-mm renal hilar metastasis was detected on CT 
before the initiation of Ipi/Nivo; B,  After two Ipi/Nivo treatment 
cycles,  re-staging CT showed a partial response of the renal hilar 
metastasis,  which was reduced to 10 mm; C,  After four treatment 
cycles of Ipi/Nivo and five cycles of nivolumab,  re-staging CT 
showed a complete response of the renal hilar metastasis,  which 
was reduced to 6 mm.
after 2 weeks.  After 4 cycles of Ipi/Nivo and one cycle of 
nivolumab,  he experienced pruritus and redness on his 
lower extremities,  which was considered to be asteatotic 
eczema.  The skin lesions were resolved by treatment 
with topical emollients and low-potency steroids in five 
weeks.  After four cycles of Ipi/Nivo and five cycles of 
nivolumab,  re-staging CT showed a CR of the hilar 
lymph node metastasis,  which was reduced to 6 mm in 
size (Fig.3C).  In addition,  other metastatic lesions showed 
noticeable decreases in diameter.  He has continued to 
receive nivolumab 240 mg monotherapy to date.
Twenty-eight months after the patient’s original diag-
nosis,  a gene panel test (FoundationOne CDx) was per-
formed to evaluate his FH gene mutation status using 
primary tumor tissues.  No genetic alterations were iden-
tified on DNA extracted from formalin-fixed,  paraffin- 
embedded tumor samples.  The patient and his family 
have not agreed to undergo genetic testing for germline 
mutations to date.  The patient has been followed up and 
has shown no recurrence for 31 months.
Discussion
We have reported a case of metastatic FH-deficient 
RCC without FH gene mutation (FH-deficient–like RCC) 
that was successfully managed with Ipi/Nivo.  The patient 
has been followed up with no recurrence for 31 months.  
To our knowledge,  only one case of FH-deficient RCC 
treated with Ipi/Nivo,  which resulted in a CR,  has been 
reported [3].
FH-deficient RCC is a very rare tumor caused by 
mutations of the FH gene,  which is located at 1q42.3-
q43m and encodes an enzyme involved in the tricar-
boxylic acid cycle.  This cycle hydrates fumarate to form 
malate [1].  FH-deficient RCC can occur sporadically,  
but it is also observed in syndromic and hereditary settings 
as part of HLRCC,  an aggressive entity defined and 
recognized in the 2016 World Health Organization clas-
sification of renal cell tumors [4].  HLRCC is an autoso-
mal dominant disorder that predisposes individuals to 
uterine and cutaneous leiomyomas and RCCs.  The 
median age at diagnosis of patients with FH-deficient 
RCCs is 43 years (range,  18 to 69 years),  with men more 
frequently affected than women (male/female ratio:  
2.3: 1).  Overall,  30% of patients have a family history 
of RCC [2].  The majority of FH-deficient RCC cases are 
metastatic at diagnosis or metastasize rapidly after diag-
nosis.  The prognosis of most FH-deficient RCCs is poor,  
with a median survival of 18 months for patients with 
metastatic disease [5].  Histologically,  FH-deficient 
RCCs show variable architectural patterns (e.g.,  papil-
lary,  tubular,  cystic,  cribriform and solid).  Most FH- 
deficient RCCs have a predominantly papillary pattern 
(52%),  and commonly have mixed growth patterns (90% 
with at least 2 different patterns).  Most cases show at 
least focal macronucleoli with perinucleolar clearing 
(halos) [2].  Immunohistochemistry (IHC) with anti-FH 
antibodies is useful for differentiating FH-deficient RCC 
and HLRCC from other renal tumors.  FH-deficient 
RCC can be detected by negative IHC results using anti- 
FH antibodies,  which are commercially available,  and 
negative FH expression on IHC is highly specific for FH- 
deficient RCC.  IHC with an anti-FH antibody was asso-
ciated with a sensitivity of 86.0-87.5% and a specificity 
of 100% [6-7].  Accurate diagnosis of FH-deficient RCC 
can be made by performing FH mutation analysis [8].  In 
the current case,  a gene panel test (FoundationOne CDx) 
was performed,  and the tumor cells demonstrated a lack 
of FH mutations.
In the present case,  some findings suggest FH- 
deficient RCC,  e.g.,  family history (such as renal cancer 
in his maternal uncle,  aunt,  and grandmother),  certain 
histologic features (such as a predominantly papillary 
architecture mixed with other patterns within the same 
tumor,  and eosinophilic inclusion-like macronucleoli 
with prominent perinucleolar halos),  and negative FH 
expression on IHC.  These findings contribute to make 
a histologically compatible diagnosis of FH-deficient 
RCC.  The term “FH-deficient RCC” has also been used 
to describe RCCs with negative FH expression on IHC 
despite an unknown genetic status at pathological diag-
nosis [8],  or RCCs with FH deficiency but lacking of 
evidence of FH germline mutation [9].   In one report,  
RCCs with negative FH expression on IHC and no 
detection of FH mutations were reported as unclassified 
RCCs or “FH-deficient–like RCCs” [7].  In the present 
case,  no FH mutation was detected in a gene panel test,  
and this finding led us to use the term “FH-deficient–like 
RCC.” In regard to the reason for the lack of FH gene 
mutation,  we consider that the discrepancy between 
genetic alterations and the protein expression of FH 
could be explained by other mechanisms,  including 
epigenetic alterations,  which were not analyzed in the 
present case.  Based on these findings,  although it is 
controversial whether this case is truly a case of FH- 
deficient RCC,  we have provided insights into the treat-
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ment of FH-deficient RCCs,  for which little evidence is 
available to date.
More recently,  the efficacy of Ipi/Nivo as a treatment 
has shown it to be a clinically important regimen for 
metastatic RCC.  Immunotherapy with checkpoint inhib-
itors,  including Ipi/Nivo,  is a standard and important 
treatment for metastatic RCC.  The CheckMate 214 trial 
showed that the Ipi/Nivo combination has a higher 
overall survival rate and objective response rate than 
sunitinib among IMDC intermediate- and poor-risk 
patients with untreated clear-cell advanced RCC [10].  
In 2018,  Ipi/Nivo became an FDA-approved first-line 
treatment option for unresectable or metastatic RCC.  
However,  few reports about the relationship between 
non-clear-cell RCC (nccRCC) and Ipi/Nivo have been 
published.  The treatment of nccRCC is based on results 
from retrospective studies,  whereas some prospective 
studies have recently become available [11].
In the current case,  diarrhea (Grade 1),  hypophysitis 
(Grade 3),  and asteatotic eczema (Grade 1) were detected 
as irAEs after the initiation of Ipi/Nivo,  and hypophysi-
tis was of significant concern.  Hypophysitis is not a rare 
irAE in patients receiving ipilimumab or checkpoint 
inhibitor combination therapy.  Patients receiving a 
combination of ipilimumab and nivolumab or PD-L1 
inhibitors are at a greater risk of developing hypophysi-
tis than those on monotherapy (6.4% vs 3.4% with ipili-
mumab,  0.4% with nivolumab,  and < 0.1% with PD-L1 
inhibitors,  respectively; p = 0.0001) [12].  Physicians 
should vigilantly monitor for irAEs while patients are 
undergoing treatment with immune checkpoint inhibi-
tors.  The development of autoimmune conditions has 
been correlated with a better response to ipilimumab 
monotherapy,  particularly with respect to grade 3/4 
irAEs.  Immunotherapy can be postponed but should 
not be stopped due to hypophysitis [13].
Alaghehbandan et al.  revealed that no association 
was found between PD-1/PD-L1 expression in tumor 
cells and TILs among 13 FH-deficient RCCs.  PD-L1 
expression in tumor cells was either weakly or strongly 
positive in 9 cases and negative in 4 cases [14].  Another 
study reported that 10 of 13 HRLCC-associated RCCs 
were positive for PD-L1 expression [15].  In the present 
case,  tumor cells were negative for PD-L1 expression,  
and there were no obvious TILs.  According to the clas-
sification of the tumor microenvironment based on 
tumor PD-L1/TIL status,  this tumor can be classified as 
type II (a PD-L1–negative tumor with no TILs indicat-
ing immune ignorance) [16].  This finding may help to 
explain why single-agent checkpoint blockage is not 
sufficient to induce an anti-tumor response.  Due to the 
lack of preexisting T-cell infiltrates,  combinations of 
checkpoint inhibitors (such as Ipi/Nivo) recruit T-cells 
into tumors and induce T-cell responses,  suggesting 
that Ipi/Nivo has potential efficacy for treating this type 
of tumor.
In conclusion,  the present findings underscore the 
possibility that Ipi/Nivo could be an effective treatment 
for FH-deficient RCC.  Going forward,  additional stud-
ies are required to evaluate the combination of Ipi/Nivo 
for the treatment of patients with FH-deficient RCC.
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